Document is current
Any future updates will be listed below
-
Authors
Dayyani, Farshid https://orcid.org/0000-0002-4970-5189
Tam, Kit
Kim, Edward J.
Ejadi, Samuel
Valerin, Jennifer
Taylor, Thomas H.
Cho, May T.
-
Funding
Funding for this research was provided by:
Chao Family Comprehensive Cancer Center
Taiho Pharmaceutical
- License Information
-
More Information
Article History
Received: 6 December 2021
Accepted: 24 February 2022
First Online: 23 May 2022
Declarations
:
: FD has received research grants (to the institution) from AstraZeneca, Bristol-Myers Squibb, Merck, Genentech/Roche, Taiho, Exelixis, Trishula, and Leap Therapeutics, has received a speaker honorarium from Amgen, Eisai, Ipsen, Exelixis, Sirtex, Deciphera, Ipsen, and Natera, and has received a consultancy honorarium from Natera, QED, Eisai, Exelixis, and Genentech/Roche. MTC has received research grant (to the institution) from Bristol-Myers Squibb, a speaker honorarium from Pfizer, Natera, Taiho, BMS, AstraZeneca, a consultancy honorarium from Amgen, Incyte, Eisai, Ipsen, Astellas, Taiho, Exelixis, QED, I-Mab, Tempus, Seattle Genetics, HelioDx, Bayer, AstraZeneca, Genentech/Roche, Pfizer, Natera, Taiho, BMS, and Basilea. EJK has received a consultancy honorarium from Taiho. The other authors declare that they have no conflict of interest.
